Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
Marie‐Julie Nokin, Alessia Mira, Enrico Patrucco, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 12

Showing 12 citing articles:

Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Oncogenic mutant KRAS inhibition through oxidation at cysteine 118
Maximilian Kramer‐Drauberg, Ettore Petrini, Alessia Mira, et al.
Molecular Oncology (2025)
Open Access
Reducing pERKs to Break “RAS”istance to Sotorasib
Steven G. Gray, Derbrenn O'Connor, Luciano Mutti, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 259-261
Closed Access
Targeting RAS and associated proteins
Matthias Müller, Roger S. Goody, Daniel Rauh
Elsevier eBooks (2025)
Closed Access
Pancreatic Cancer: Pathogenesis and Clinical Studies
Kexun Zhou, Yingping Liu, Chuanyun Tang, et al.
MedComm (2025) Vol. 6, Iss. 4
Open Access
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
Panagiotis Filis, Dimitrios Salgkamis, Alexios Matikas, et al.
Drug Discovery Today (2024), pp. 104250-104250
Open Access | Times Cited: 2
Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C
Anna E. Maciag, James P. Stice, Bin Wang, et al.
Cancer Discovery (2024) Vol. 15, Iss. 3, pp. 578-594
Open Access | Times Cited: 2
First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives
Qi He, Xiaoyan Liu, Liyan Jiang, et al.
Cancer Biology & Therapy (2024) Vol. 26, Iss. 1
Open Access | Times Cited: 1
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies
Luigi Liguori, Fabio Salomone, Angela Viggiano, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 205, pp. 104554-104554
Open Access | Times Cited: 1
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer
L. Amato, Daniela Omodei, Caterina De Rosa, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 3941-3941
Open Access | Times Cited: 1
Ductal pancreatic cancer interception by FGFR2 abrogation
Claudia Tonelli, Astrid Deschênes, Victoria Gaeth, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
Alexandria TM Lee, Misako Nagasaka
Lung Cancer Targets and Therapy (2024) Vol. Volume 15, pp. 169-176
Open Access
Page 1

Scroll to top